Mitiglinide/voglibose

Drug Profile

Mitiglinide/voglibose

Alternative Names: Glubes; KMV-0207; Voglibose/mitiglinide

Latest Information Update: 02 Dec 2016

Price : $50

At a glance

  • Originator Kissei Pharmaceutical; Takeda
  • Class Inositol phosphates; Isoindoles; Small molecules; Sugar alcohols
  • Mechanism of Action Alpha-glucosidase inhibitors; Insulinotropin agonists; Potassium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Type 2 diabetes mellitus

Most Recent Events

  • 01 Dec 2015 Clinical trials in Type-2 diabetes mellitus (Treatment-experienced) in Japan (PO) (UMIN000019833)
  • 22 Jul 2011 Launched for Type-2 diabetes mellitus in Japan (PO) - First Global Launch
  • 22 Apr 2011 Registered for Type-2 diabetes mellitus in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top